Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SABBOBCATon Oct 18, 2021 1:19pm
289 Views
Post# 34018825

"That" time of year

"That" time of year

So not that TH has bumbled along and we are well into fiscal Q4, we are approaching that time of year when bonuses and options are going to be dolled out. Yes, this is still months away still, but what is also potentially months away? Potential efficacy signals and/or partnership announcements. I get the feeling we are all getting a little too optimistic on the timing of these positive announcements. They are messaging that there will be a MTD announcement before the end of the year. I don’t doubt that, but I think that is all we will get.


As per the usual TH style, there will be a dearth of information until after bonus season, then they will puke out a bunch of data/news all at once to try and buoy the neglected and depressed share price so they can do an overly dilutive financing with a C rated syndicate.


I feel I am following in Spartrap’s footsteps and am becoming very cynical, but what reason or indication has the company given to show this won’t come true?

NASH program…delayed… NASH partnership… delayed… Phase 1A and MTD… delayed… sales growth… delayed/lower trajectory.


Attempts at positive news cycles from TH always seem to hit in the spring after options have been granted, then taper off in Oct/Nov. Last year was the exception, but then guess what happened a dilutive financing that was a knee jerk reaction to some doom and gloom put out by B/C rated Canadian bankers.
 

Sure, there is some token buying by the board, but no one is really doubling down in advance of good news. I hope I am wrong. I hope we see more insider buying, particularly from dubious Dubuc, or else I am resigning myself to the view that we are screwed for another 6 months.
 

<< Previous
Bullboard Posts
Next >>